51 results about "Basal cell" patented technology

The invention discloses a construction method and application of a mouse airway organoid inflammation model, and relates to the technical field of biology. The construction method comprises the following steps: (1) taking a mouse airway tissue, digesting with digestive juice, and centrifuging to obtain a cell suspension; (2) centrifuging the cell suspension, discarding the supernatant, adding matrigel, uniformly mixing, incubating, and culturing by using an airway organoid complete medium; (3) adding a cell recovery solution into the cells cultured in the step (2), incubating, degumming, centrifuging, discarding supernatant, adding matrigel, uniformly mixing, incubating, and adding an airway organ complete culture medium for continuous culture; and (4) adding 1-20 [mu] g / ml of LPS into the airway organoid complete culture medium, and incubating. The AO constructed by the invention covers four main cell types of cilia cells, goblet cells, basal cells and rod-like cells, causes epithelial injury in the AO and expression of AO inflammatory factors, and can provide reference for development of CRD new drugs.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

The invention relates to an algin sulfate (PMGS) patch as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the application, the fucoidan polysaccharide sulfate (PMGS) is used as a main raw material of the microneedle for the first time, the needle tip is completely composed of PMGS, the PMGS plays a role in medicine and adjuvant integration, on one hand, the PMGS is used as a needle tip matrix to provide enough mechanical strength to pierce warts and surrounding skin and is more suitable for related warts with obvious skin thickening, and on the other hand, the PMGS is diffused and released at the position where viruses are located, so that the effect of preventing and treating warts is achieved. The skin wart treatment effect is achieved by preventing virus from entering and enhancing skin immunity, compared with a previous authorized patent scheme, the problems that PMGS as macromolecular polysaccharide enters the skin and is insufficient in absorption are solved in a microneedle mode, PMGS can be directly delivered to basal layer cells where HPV is located, and fixed-point drug delivery is achieved.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

According to the pluripotent stem cell-derived human mammary gland organoid and the construction method thereof, the human mammary gland organoid is obtained through the following multi-stage induction culture: first-stage culture: culturing for 1-3 days by using a first culture medium to obtain a surface ectoderm stage organoid expressing a surface ectoderm marker K8 / K18; second-stage culture: culturing for 1-3 days by using a second culture medium to obtain a mammary gland substrate-like organ which has bright epithelium and expresses mammary gland substrate markers EDAR and LEF1; third-stage culture: culturing for 3-5 days by using a third culture medium; fourth-stage culture: culturing for 3-5 days by using a fourth culture medium; a fifth culture medium is used for culture for 8-12 days to form an epithelial structure with basal cells and lumen cells, a mammary gland physiological microenvironment simulated by mesenchymal cells and vascular endothelial cells and a mature mammary gland organ with a lactation function. According to the invention, the mature mammary gland organ with a lactation function is successfully constructed.

The invention discloses a tissue engineering integrated trachea regeneration construction method based on a frame structure scaffold and application. A multi-tissue-structure integrated gas pipe is constructed based on a 3D printing bioelastomer frame structure support, and the complex structure and physiological functions of a natural gas pipe are highly simulated. The preparation method comprises the following steps: firstly, by utilizing the characteristic that temperature-sensitive hydrogel Pluronic F-127 becomes semi-solid gel at 37 DEG C and is liquefied at a low temperature of 4 DEG C, and by adopting a strategy that the temperature-sensitive hydrogel is sacrificed after occupying, the patterned distribution of chondrocytes and fibroblasts on a two-dimensional plane is realized; secondly, simulating a three-dimensional tubular trachea structure through a 2D-3D (two-dimensional to three-dimensional) rolling assembly strategy, and realizing the ordered regeneration of C-shaped cartilage ring / O-shaped fiber ring alternate distribution and axial strip-shaped fiber bundle triple structures under the skin of the nude mouse. And finally, successfully extracting the airway mucosa epithelium, separating and amplifying enough airway basal cells in vitro, and loading the airway basal cells to the inner wall of the regenerated trachea by utilizing the photo-crosslinking hydrogel, thereby realizing the function simulation of the airway epithelium and enhancing the physiological functionality.

A method for rapidly and efficiently inducing multiple human airway epithelium in vitro models for a long time relates to the technical field of organoid culture.The method comprises the steps that firstly, a clinical lung tissue sample is induced and differentiated to form a cilia inward lung airway organoid, the cilia inward lung airway organoid is digested into single cells, and multiplication culture is conducted through a basal cell culture medium; the obtained basal cells are subjected to induced differentiation to form cilia outward lung airway organs and a gas-liquid interface culture model. The two types of models can successfully simulate the functional cellular morphology of the human airway epithelium in vitro, can be used as experimental models for disease modeling, drug screening, toxicity testing and the like, and can simulate biological models of the human airway structure and function. The method can solve the problems that clinical samples are difficult to obtain and primary lung epithelial cells have limited passage times in the construction process of lung airway organs, and realizes long-term rapid and efficient induction of various human airway epithelium in-vitro models.

The invention relates to the technical field of biological medicine, provides novel application of IL-17a, and particularly relates to application of an IL-17a inhibitor in preparation of a medicine for treating age-related olfactory dysfunction. The research result shows that the expression increase of the IL-17a can trigger an inflammation signal and damage the olfactory function. Administration of the IL-17a inhibitor Y-320 or a neutralizing antibody promotes sensory neuron regeneration in the olfactory epithelium (OE) and reverses age-related respiratory metaplasia. In addition, conditional knockout of IL-17a in T cells can promote olfactory epithelium regeneration by promoting recruitment and differentiation of horizontal basal cells (HBCs) into globular basal cells (GBCs). In general, the research of the invention determines the previously undetermined effect of the IL-17a in olfactory epithelium regeneration and age-related olfactory function defects, and provides evidence for the IL-17a as a potential therapeutic target for olfaction of the elderly.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The present invention relates to the field of cell culture, and in particular to a culture medium and a culture method for stem cell-like memory T lymphocytes. By adding a GSK-3β inhibitor, an mTOR inhibitor or a PI3K inhibitor, as well as adding IL-15 and using magnetic bead sorting, the present invention can provide a large number of stem cell-like memory T lymphocytes with memory characteristics and low differentiation status, which can be used alone for tumor treatment, or as a basic cell for CAR-T treatment to obtain better anti-tumor ability and survival and proliferation ability than central memory lymphocytes or effector lymphocytes in clinical practice, which has great significance and value to the entire field of cell research and application.

To provide a method for producing a sheet-like cell culture showing a three-layer structure including a cell layer of superficial cells, a cell layer of intermediate cells, and a cell layer of basal cells, in this order. Provided is a method for producing a sheet-like cell culture that includes culturing a progenitor cell population in a second compartment separated from a first compartment via a porous member to form a sheet-like cell culture in the second compartment. The sheet-like cell culture includes a cell layer of superficial cells derived from the progenitor cell population, a cell layer of intermediate cells derived from the progenitor cell population, and a cell layer of basal cells derived from the progenitor cell population, in this order. The first compartment holds an induction medium containing retinoic acid, bone morphogenetic protein (BMP), and fibroblast growth factor (FGF).

The invention belongs to the cross technical field of biomedical detection and information technology, and particularly relates to a detection kit, system and method for cancer immunotherapy curative effect prediction. The detection kit comprises a combination of a first detection reagent for specifically detecting the LAMC2 gene or protein and a second detection reagent for specifically detecting the SPP1 gene or protein. Research finds that in a complex tumor microenvironment, LAMC < 2 + > basal cells and SPP1 < + > macrophages, which are respectively derived from specific subgroups of tumor cells and immune cells, jointly form a key biological signal capable of remarkably influencing immunotherapy response according to the existence and the quantity of the two specific subgroups of the LAMC < 2 + > basal cells and the SPP1 < + > macrophages. By jointly detecting the pair of biomarkers with a synergistic effect, the problems of insufficient prediction accuracy and incapability of reflecting tumor microenvironment heterogeneity caused by dependence on PD-L1, TMB and other single markers in the prior art are solved, and the technical effect of remarkably improving the sensitivity and reliability of immunotherapy curative effect prediction is achieved.

The present application discloses a Cux1 inhibitor and its uses. In the present application, the single-cell transcriptome atlas of a chronic skin dryness mouse model was innovatively studied, and several potential therapeutic targets were discovered through bioinformatics analysis. In the present application, novel skin dryness-induced Cux1+ proliferative basal cells were discovered, the mechanism of action and influence were confirmed through ligand-receptor research, and it was verified through gene knockout experiments that Cux1-positive basal cells are closely related to the epidermal hyperplasia in psoriasis patients. Therefore, Cux1 inhibitors can be widely used to treat epidermal hyperplasia skin diseases. The present application also newly designed an inhibitor for reducing the expression level of Cux1.

The technology described herein is directed to engraftment methods for airway basal cells into the respiratory tract of a subject, following removal of epithelial cells of the respiratory tract. Also described herein are methods of treating a respiratory tract disease or a respiratory tract injury.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

The invention relates to a method for differentiating mesenchymal stem cells into adipose cells, which comprises the following steps: (1) culturing early passage mesenchymal stem cells to a confluence degree close to 100%, and ensuring enough basic cell quantity; (2) replacing the basic culture medium with a fat induction culture medium, and performing induced differentiation for 14-21 days; (3) observing a saturated oil red O dyeing result; and (4) the method can be applied to differentiation of mesenchymal stem cells in animal cell culture meat into adipocytes to form lipids, and is suitable for differentiation of mesenchymal stem cells into adipocytes in stem cell treatment and health care.

The invention discloses a skin cell nucleus nutritional agent containing traditional Chinese medicine components and capable of improving ichthyosis and a preparation method, and relates to the technical field of preparation of skin cell nucleus nutritional agents. Comprising the following raw materials: modified vitamin A propionate, a traditional Chinese medicine extract, modified hydrogenated lecithin, squalane, beewax, stearyl alcohol, vaseline, glycerin, sodium hyaluronate, beta-glucan, propylene glycol, potassium cetyl phosphate, a preservative, allantoin, deionized water, triethanolamine and a lipid solvent. According to the invention, the modified tretinoin propionate is added, and the modified tretinoin propionate is subjected to double-grafting modification through glycyrrhetinic acid-hyaluronic acid oligosaccharide and is gently combined with a basal cell tretinoin receptor in a targeted manner, so that excessive proliferation of basal cells can be inhibited, and normal differentiation of keratinocytes can be promoted; wherein the glycyrrhetinic acid component can resist inflammation, relieve and reduce self-irritation, and the hyaluronic acid oligosaccharide can improve targeting and transdermal efficiency, avoid light / oxygen degradation and provide a core regulation effect for restoring the 28-day metabolic cycle of basal cells.

The present invention relates to a method for producing respiratory organoids by proliferating and differentiating respiratory epithelial cells. [Solution] Unlike conventional respiratory organoids in which epithelial cells present at the apical end of the respiratory tract develop inside the organoid, the respiratory organoid of the present invention has a morphology in which the ciliated structure, which is made up of epithelial cells, is located in the outer layer of the organoid, secretory cells are located inside, and stem cell-like basal cells present at the base of the respiratory tissue are also located inside the organoid. This morphology is similar to that of actual respiratory tissue and has been observed to exhibit normal functions of epithelial cells, such as the motility of ciliated cells. Therefore, by manufacturing organoids using the manufacturing method of the present invention, it is possible to manufacture respiratory organoids that can accurately mimic actual tissue.

The invention relates to the field of biological medicine, in particular to application of AREG in chronic sinusitis with nasal polyp eosinophilic inflammation. According to the invention, the nasal epithelial cell, especially the basal cell, is found for the first time, is a cell source of the AREG and is also one of important target cells acted by the AREG. AREG promotes proliferation of epithelial basal cells and inhibits differentiation of the basal cells into cilia cells, resulting in structural abnormality and function impairment of human CRSwNP tissue epithelial barriers. The AREG chemotactices and activates human peripheral blood eosinophilic granulocytes, and the receptor EGFR antagonist Erlotinib of the AREG can antagonize the effect of the AREG on the eosinophilic granulocytes. The AREG secreted by neutralizing epithelial cells or other inflammatory cells can effectively relieve the eosinophilic inflammatory reaction of the nasal mucosa of the CRSwNP mouse model and recover the damaged epithelial barrier function of the nasal mucosa of the mouse. It is proved that when the neutralizing antibody of AREG or EGFR or shRNA is used as the antagonist, the eosinophilic inflammatory response of CRSwNP can be relieved by inhibiting the effect of AREG.

The invention belongs to the technical field of cell culture, and particularly relates to a bronchiectasis patient airway epithelial basal cell separation and culture method, which comprises: obtaining bronchial tissue of a bronchiectasis patient, stripping connective tissue of the bronchial tissue, and retaining cartilage rings; longitudinally cutting the completely stripped bronchial tissue along the tracheal ring to expose the inner membrane surface of the bronchial, then soaking the bronchial tissue in a Dispase II dispersing enzyme solution to digest, and collecting the dissociated bronchial tissue; the dissociated bronchial tissue is soaked in a Dispase II dispersozyme solution, and the bronchial tissue is blown and beaten; after blowing and beating are completed, stopping digestion by using a serum-free culture medium, and collecting a cell suspension; filtering and centrifuging the cell suspension, discarding supernate, and collecting precipitated cells; and placing the precipitated cells in an amplification culture medium for cell amplification and subculture. The purity of the airway epithelial basal cells of the bronchiectasis patient separated by the method is high, and the proliferation capacity and the reaction capacity of the cells are good.

The invention discloses a lung tissue organoid culture method. The method comprises the following steps: firstly, carrying out three-dimensional differentiation culture on matrigel by utilizing lung basal cells in vitro to construct an organoid with alveolar epithelium characteristics; then, the organ is transplanted into the spleen of a recipient animal subjected to ectopic surgery (shifted to subcutaneous tissues). The rich blood vessel network and the unique microenvironment of the spleen greatly promote rapid vascularization, structural remodeling and functional maturation of organoids, and lung tissue highly simulating natural alveolus is formed. The invention overcomes the defects of insufficient vascularization and immature function of the existing organ-like model, provides an excellent in-vivo platform for researching lung development and disease mechanisms and carrying out drug screening and toxicological evaluation, and has important application value in the field of regenerative medicine.

Provided herein are ex vivo methods of engineering or culturing a submucosal gland (SMG) organoid, comprising isolating submucosal gland basal cells and / or myoepithelial cells (e.g., human cells), and / or submucosal gland stem and / or progenitor cells (e.g., human cells), and culturing such cells with an agonist or ligand of ERBB (e.g., in a three- dimensional matrix). Also provided herein are SMG organoid engineered or cultured ex vivo. Also provided herein are methods of identifying an agent that reduces airway mucus production using an ex vivo SMG organoid described herein. Also provided herein is a method of treating a hypersecretory airway disorder or disease, or a disorder associated with an increased secretion from submucosal glands, in a subject, comprising administering to the subject an agent that inhibits ERBB.

The present disclosure relates to anti-basal cell adhesion molecule (BCAM) antibody-drug conjugates, wherein the anti-BCAM antibody is conjugated to an anti-tumor compound via a linker, pharmaceutical compositions comprising the anti-BCAM antibody-drug conjugates, and methods of treating cancer by administering an effective amount of the anti-BCAM antibody-drug conjugate to a subject in need thereof.

The application discloses a human mammary gland organoid derived from pluripotent stem cells and a construction method thereof, and the mammary gland organoid is obtained through the following multi-stage induction culture: first stage culture: culturing for 1-3 days by using a first culture medium to obtain a surface ectoderm stage organoid expressing surface ectoderm markers K8 / K18; second stage culture: culturing for 1-3 days by using a second culture medium to obtain a mammary gland basement membrane-like organoid having a bright epithelium and expressing mammary gland basement membrane markers EDAR and LEF1; third stage culture: culturing for 3-5 days by using a third culture medium; fourth stage culture: culturing for 3-5 days by using a fourth culture medium; and fifth stage culture: culturing for 8-12 days by using a fifth culture medium to form an epithelial structure having basal cells and luminal cells, a mammary gland physiological microenvironment simulated by mesenchymal cells and vascular endothelial cells and a mature mammary gland organoid having a lactation function. The application successfully constructs the mature mammary gland organoid having the lactation function.

To provide a method for preparing a respiratory organoid by proliferating and differentiating respiratory epithelial cells.SOLUTION: Unlike conventional respiratory organoids in which epithelial cells existing in an apical region of a respiratory organ are generated on an interior of the organoid, the respiratory organoid of the present disclosure is shown in a form in which ciliated structures, which are epithelial cells, are located in an outer layer of the organoid, secretory cells are present on the interior, and basal stem cells existing at a base of respiratory tissue are also present on the interior of the organoid. It has a form similar to an actual respiratory tissue, and it was observed to exhibit normal functions of the epithelial cells, such as motility of ciliated cells. Therefore, when an organoid is prepared using the preparation method of the present disclosure, a respiratory organoid that can well mimic the actual tissue can be prepared.SELECTED DRAWING: Figure 1

A non-invasive optical system for stimulating hair regeneration is disclosed. The non-invasive optical system comprises a femtosecond laser unit used for generating femtosecond laser; and the optical focusing unit is used for focusing the femtosecond laser to a basal layer of skin tissue so as to stimulate basal cells in the basal layer to form hair follicles and further stimulate hair regeneration. According to the non-invasive optical system, femtosecond laser directly acts on basal cells through cuticles, no wound is caused, hair follicles can be formed within one day after single treatment, and the non-invasive optical system has good transformation application prospects.

Described herein are compositions and methods for potent and long-lasting gene editing in a cell. The gene editing may result in an increase in function of a gene product. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. The presently disclosed compositions comprise a lipid composition, which can comprise an ionizable cationic lipid, a sterol, a phospholipid, and a selective organ targeting lipid. Also described herein are methods for treating a disease or disorder, such as a lung disease or disorder, involving the presently disclosed compositions.

The present disclosure relates to methods of differentiating pluripotent stem cells or lung progenitor cells into epithelial or basal cells. The present disclosure also relates to epithelial or basal cells made by such methods, organoids containing such epithelial or basal cells, and methods of using the same. The present disclosure also relates to differentiation media for use in the same.